Overview of Dermatological Manifestations Associated with the COVID-19 Infection
Skin Therapy Lett. 2024 Mar;29(2):7-9.ABSTRACTCOVID-19 is an infectious disease caused by SARS-CoV-2 that is characterized by respiratory symptoms, fever, and chills.[1] While these systemic symptoms are widely known and well understood, there have also been reports of dermatological manifestations in patients with COVID-19. These manifestations include chilblain-like lesions, maculopapular lesions, urticarial lesions, necrosis, and other varicella-like exanthems.[2] The pathogenesis of these lesions are not well understood, but the procoagulant and pro-inflammatory state induced by COVID-19 infections may be contributing ...
Source: Skin Therapy Letter - April 4, 2024 Category: Dermatology Authors: Heli Patel Linh Tran Steven R Feldman Source Type: research
An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa
Skin Therapy Lett. 2024 Mar;29(2):1-6.ABSTRACTHidradenitis suppurativa (HS) is a severe, debilitating, chronic inflammatory skin disease characterized by recurrent painful nodules, abscesses and draining sinus tracts in intertriginous areas. While this condition appears to stem from follicular unit dysfunction, its cause is multifactorial and the exact pathogenesis has yet to be fully elucidated. These factors make treatment selection challenging and contribute to variable therapeutic response among affected patients. Typical regimens consist of a combination of medical and surgical modalities, tailored to individual respo...
Source: Skin Therapy Letter - April 4, 2024 Category: Dermatology Authors: Austinn Miller Parastou Shahzeidi Michael Bernhardt Source Type: research
Overview of Dermatological Manifestations Associated with the COVID-19 Infection
Skin Therapy Lett. 2024 Mar;29(2):7-9.ABSTRACTCOVID-19 is an infectious disease caused by SARS-CoV-2 that is characterized by respiratory symptoms, fever, and chills.[1] While these systemic symptoms are widely known and well understood, there have also been reports of dermatological manifestations in patients with COVID-19. These manifestations include chilblain-like lesions, maculopapular lesions, urticarial lesions, necrosis, and other varicella-like exanthems.[2] The pathogenesis of these lesions are not well understood, but the procoagulant and pro-inflammatory state induced by COVID-19 infections may be contributing ...
Source: Skin Therapy Letter - April 4, 2024 Category: Dermatology Authors: Heli Patel Linh Tran Steven R Feldman Source Type: research
An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa
Skin Therapy Lett. 2024 Mar;29(2):1-6.ABSTRACTHidradenitis suppurativa (HS) is a severe, debilitating, chronic inflammatory skin disease characterized by recurrent painful nodules, abscesses and draining sinus tracts in intertriginous areas. While this condition appears to stem from follicular unit dysfunction, its cause is multifactorial and the exact pathogenesis has yet to be fully elucidated. These factors make treatment selection challenging and contribute to variable therapeutic response among affected patients. Typical regimens consist of a combination of medical and surgical modalities, tailored to individual respo...
Source: Skin Therapy Letter - April 4, 2024 Category: Dermatology Authors: Austinn Miller Parastou Shahzeidi Michael Bernhardt Source Type: research
Overview of Dermatological Manifestations Associated with the COVID-19 Infection
Skin Therapy Lett. 2024 Mar;29(2):7-9.ABSTRACTCOVID-19 is an infectious disease caused by SARS-CoV-2 that is characterized by respiratory symptoms, fever, and chills.[1] While these systemic symptoms are widely known and well understood, there have also been reports of dermatological manifestations in patients with COVID-19. These manifestations include chilblain-like lesions, maculopapular lesions, urticarial lesions, necrosis, and other varicella-like exanthems.[2] The pathogenesis of these lesions are not well understood, but the procoagulant and pro-inflammatory state induced by COVID-19 infections may be contributing ...
Source: Skin Therapy Letter - April 4, 2024 Category: Dermatology Authors: Heli Patel Linh Tran Steven R Feldman Source Type: research
An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa
Skin Therapy Lett. 2024 Mar;29(2):1-6.ABSTRACTHidradenitis suppurativa (HS) is a severe, debilitating, chronic inflammatory skin disease characterized by recurrent painful nodules, abscesses and draining sinus tracts in intertriginous areas. While this condition appears to stem from follicular unit dysfunction, its cause is multifactorial and the exact pathogenesis has yet to be fully elucidated. These factors make treatment selection challenging and contribute to variable therapeutic response among affected patients. Typical regimens consist of a combination of medical and surgical modalities, tailored to individual respo...
Source: Skin Therapy Letter - April 4, 2024 Category: Dermatology Authors: Austinn Miller Parastou Shahzeidi Michael Bernhardt Source Type: research
Overview of Dermatological Manifestations Associated with the COVID-19 Infection
Skin Therapy Lett. 2024 Mar;29(2):7-9.ABSTRACTCOVID-19 is an infectious disease caused by SARS-CoV-2 that is characterized by respiratory symptoms, fever, and chills.[1] While these systemic symptoms are widely known and well understood, there have also been reports of dermatological manifestations in patients with COVID-19. These manifestations include chilblain-like lesions, maculopapular lesions, urticarial lesions, necrosis, and other varicella-like exanthems.[2] The pathogenesis of these lesions are not well understood, but the procoagulant and pro-inflammatory state induced by COVID-19 infections may be contributing ...
Source: Skin Therapy Letter - April 4, 2024 Category: Dermatology Authors: Heli Patel Linh Tran Steven R Feldman Source Type: research
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
1726 nm Lasers for the Treatment of Acne Vulgaris
Skin Therapy Lett. 2024 Jan;29(1):5-7.ABSTRACTThe treatment of acne vulgaris traditionally consists of a combination of topical and oral medications. The use of lasers to treat this condition has been an area of increasing research, and several types have previously been used in the treatment of acne. New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology. This laser wavelength demonstrates substantial potential as a safe and effective therapeutic option for moderate to severe acne without the risks of systemic therapy. This paper reviews the 1726 nm lasers for acne...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Julie Bittar Perry Hooper Jeffrey S Dover Source Type: research
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
1726 nm Lasers for the Treatment of Acne Vulgaris
Skin Therapy Lett. 2024 Jan;29(1):5-7.ABSTRACTThe treatment of acne vulgaris traditionally consists of a combination of topical and oral medications. The use of lasers to treat this condition has been an area of increasing research, and several types have previously been used in the treatment of acne. New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology. This laser wavelength demonstrates substantial potential as a safe and effective therapeutic option for moderate to severe acne without the risks of systemic therapy. This paper reviews the 1726 nm lasers for acne...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Julie Bittar Perry Hooper Jeffrey S Dover Source Type: research
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
1726 nm Lasers for the Treatment of Acne Vulgaris
Skin Therapy Lett. 2024 Jan;29(1):5-7.ABSTRACTThe treatment of acne vulgaris traditionally consists of a combination of topical and oral medications. The use of lasers to treat this condition has been an area of increasing research, and several types have previously been used in the treatment of acne. New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology. This laser wavelength demonstrates substantial potential as a safe and effective therapeutic option for moderate to severe acne without the risks of systemic therapy. This paper reviews the 1726 nm lasers for acne...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Julie Bittar Perry Hooper Jeffrey S Dover Source Type: research
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
1726 nm Lasers for the Treatment of Acne Vulgaris
Skin Therapy Lett. 2024 Jan;29(1):5-7.ABSTRACTThe treatment of acne vulgaris traditionally consists of a combination of topical and oral medications. The use of lasers to treat this condition has been an area of increasing research, and several types have previously been used in the treatment of acne. New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology. This laser wavelength demonstrates substantial potential as a safe and effective therapeutic option for moderate to severe acne without the risks of systemic therapy. This paper reviews the 1726 nm lasers for acne...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Julie Bittar Perry Hooper Jeffrey S Dover Source Type: research
